VBI Vaccines Inc. will voluntarily delist from the Toronto Stock Exchange at the close of trading on March 23.
The Cambridge, Mass.-based company said "very limited trading activity" of its shares on the TSX no longer justifies the costs of maintaining a dual-listing. Further, delisting from the TSX will allow VBI to create a central marketplace for its shares on Nasdaq, where it will continue to trade under the symbol VBIV.
The company will continue to have a significant operational presence in Ottawa.
VBI develops vaccines for use in the fields of infectious disease and immuno-oncology.
